Back to results
US 6,887,849 B2Granted
Long lasting synthetic glucagon-like peptide {GLP-1}
AssigneeConjuChem, Inc.
InventorsDominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
Life of this patent
Estimating the term…
Abstract
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
Claims9
The compound D-Ala8 GLP-1 (7-36)-Lys37(ε-(AEEA)-MPA)-NH2.
Dependencies are inferred from the claim text.